- Home
- / ASLAN Pharmaceuticals
ASLAN Pharmaceuticals
Stock Price
$0.6
2024-09-04
Market Capitalization
$1.7 M
2024-09-04
Revenue
$12 M
FY, 2023
ASLAN Pharmaceuticals Summary
Company Summary
- Overview
- ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company developing novel therapeutics for global markets. The Company targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
- Type
- Public
- Status
- Active
- HQ
- SG | view all locations
- Website
- http://aslanpharma.com/
- Cybersecurity rating
Table of Contents
Key People
Stephen Doyle, Chief Business Officer
Kenneth Kobayashi, Chief Medical Officer
Ben Goodger, General Counsel
LocationsView all
4 locations detected
Collingwood, Victoria
Australia
58 Gipps St
Shanghai Shi
China
83 Wanhangdu Rd, Jingan Qu
Taipei City
Taiwan
ASLAN Pharmaceuticals Financials
Summary Financials
- Net income (Q1, 2024)
- ($9.9M)
- Cash (Q1, 2024)
- $18.4M
- EBIT (Q1, 2024)
- ($9.3M)
- Enterprise value
- $9.8M